Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer
Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
Related Articles
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.
Fox Chase Cancer Center Welcomes Dr Alexander R. Vartanov
Fox Chase Cancer Center hired Alexander R. Vartanov, MD, as an assistant professor in the Department of Bone Marrow Transplant and Cellular Therapies.
Phase 3 Study of TAR-200/Cetrelimab Is Discontinued in MIBC
The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.
Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis
Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.
Perioperative Pembrolizumab Meets EFS End Point in Newly Diagnosed, Resected Stage III/IVA HNSCC
Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.
PARP1-Selective Inhibitors Generate Excitement in Solid Tumors
Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.
ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer
Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.
CINtec PLUS Receives WHO Endorsement in Cervical Cancer Prevention Guidelines
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC
An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.
Dato-DXd Fails to Show OS Benefit in Pretreated HR+/HER2-Low or -Negative Metastatic Breast Cancer
No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.